PV Reporter

01/30/2026

Partner Corner: PV In Focus – Fort Lauderdale

Join us for a day of community and education on polycythemia vera!

📍 Fort Lauderdale, FL
📅 February 28th, 2026
🕣 8:30 AM – 2:00 PM

Topics include:

- PV overview and treatment options
- A patient's perspective
- Self-advocacy
- Mental health

Breakfast and lunch provided.

Register at PVInFocus.com

01/27/2026

Ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate response to or loss of response to existing treatments

Ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate response to or loss of response to existing treatments BURLINGTON, Mass, Jan. 27, 2026–PharmaEss...

01/27/2026

Novartis hasn’t given up on its MorphoSys-originated BET inhibitor pelabresib, but it needs to carry out another phase 3 study before filing in the US – and details of that trial have just been listed on clinicaltrials.gov.

https://www.oncologypipeline.com/apexonco/novartis-perseveres-pelabresib

A new phase 3, Manifest-3, will start in April to support US filing.

01/16/2026

FDA decision on Rusfertide expected by Aug. 2026 according to this article 👇

Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development. Hundreds of millions of dollars are on the line.

01/16/2026

Interesting research - Scientists Identify Pre-Cancerous States in Seemingly Normal Aging Tissues

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

01/12/2026

New targeted treatment offers hope for people with myelofibrosis

https://www.scimex.org/newsfeed/new-targeted-treatment-offers-hope-for-people-with-myelofibrosis

01/06/2026

Big News for the Myelofibrosis Community! 📣

For a long time, many Myelofibrosis patients in the early stages have been told to "watch and wait." But a new 2025 study suggests that "acting early" might be the better path.

The study found that using Interferon early on can help reduce bone marrow scarring and lower the "burden" of the disease. This is a huge win for those looking for proactive ways to manage their health!

Check out the article to learn more about these findings:
👉 https://www.pvreporter.com/interferon-for-myelofibrosis-2025-study-challenges-watch-and-wait/

Early interferon treatment in pre-fibrotic myelofibrosis may slow disease progression, reduce fibrosis, and challenge the long-standing watch-and-wait approach.

01/05/2026

📰 Alright, now that the holidays are over it's time for a good news update:

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

https://financialpost.com/pmn/business-wire-news-releases-pmn/takeda-and-protagonist-announce-submission-of-new-drug-application-nda-for-rusfertide-for-treatment-of-polycythemia-vera-pv

01/01/2026

Wishing you a healthy, Happy New Year!

12/23/2025

Warm wishes for a joyful holiday season filled with love, laughter, and cherished moments. Happy Holidays!

12/19/2025

Teenage me wanted to shred solos and "make bad decisions." 🎸 Life had other plans. It skipped the tour bus and put me on a different stage.

Now I’m a Patient Advocate, Educator, and occasional Myth Buster. 🎤 Is it what I expected? No. Is it better than a burnt-out music career? Hell yeah!

This work matters, and I’m just getting tuned up. See you in 2026 to continue the mission Together.

Enjoy the holidays and keep shredding. 🤘

12/12/2025

👍Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis

https://www.ajaxtherapeutics.com/press-release/ajax-therapeutics-receives-orphan-drug-designation-from-the-u-s-fda-for-aj1-11095-for-the-treatment-of-myelofibrosis/